Comparing two long-acting insulins for Tunisian patients with type 2 diabetes
Part of Hormones & metabolism clinical trials.
This study compares two types of long-acting insulin: a newer one called Glargine and an older one called NPH. You'll use a continuous glucose monitor to track your blood sugar, and the study will see which insulin helps control your diabetes better with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You have type 2 diabetes and have been taking NPH insulin for 5 to 10 years.
- You take NPH insulin twice a day, with a stable dose of your current diabetes pills for at least 2 months.
- Your last HbA1c (average blood sugar over 3 months) should be between 7% and 10%.
- You need to be able to use a continuous glucose monitor (a device that checks your sugar levels automatically).
- You cannot be pregnant or breastfeeding, and you must not have severe kidney problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests a new experimental drug (NNC0487-0111) designed to help regulate insulin levels in adults with type 2 diabetes. Researchers want to see if it works safely and effectively when combined with your current diabetes medications.
This study looks at what happens when people with type 2 diabetes switch from a short course of intensive insulin therapy to different daily diabetes medicines. It aims to find which option helps keep blood sugar under control and might be easier for you.
This study compares two different two-drug combinations for people recently diagnosed with type 2 diabetes. It aims to find which combination works better to control blood sugar and improve overall health.
This study tests whether a new injection that combines insulin with liraglutide works better than standard premixed insulin for people with type 2 diabetes. It aims to improve blood sugar control and simplify treatment.
This study compares a continuous “under the skin” diabetes medicine (called beinaglutide) with an insulin pump (CSII) in people who were recently diagnosed with type 2 diabetes. It aims to see which approach works better and is safer for controlling blood sugar.
This study tests a new once-daily insulin (GZR4) against an approved insulin (degludec) in people with type 2 diabetes to see how well it controls blood sugar. You may qualify if you are already using a stable dose of background insulin.
Hear when a new Diabetes Mellitus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.